Compare PAX & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAX | CDNA |
|---|---|---|
| Founded | 1988 | 1998 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2020 | 2007 |
| Metric | PAX | CDNA |
|---|---|---|
| Price | $11.22 | $47.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $18.00 | ★ $28.00 |
| AVG Volume (30 Days) | 1.0M | ★ 1.3M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | ★ 4.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.13 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $12.99 | $16.01 |
| Revenue Next Year | $16.52 | $11.31 |
| P/E Ratio | $25.65 | ★ $22.15 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $10.55 | $11.27 |
| 52 Week High | $17.80 | $49.76 |
| Indicator | PAX | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 52.18 | 74.96 |
| Support Level | $10.79 | $16.70 |
| Resistance Level | $11.56 | $49.76 |
| Average True Range (ATR) | 0.34 | 2.23 |
| MACD | 0.05 | 0.42 |
| Stochastic Oscillator | 60.96 | 85.15 |
Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.